IPO Year: 2021
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/7/2022 | $7.50 | Equal-Weight | Morgan Stanley |
SC 13D/A - Senti Biosciences, Inc. (0001854270) (Subject)
SC 13G - Senti Biosciences, Inc. (0001854270) (Subject)
SC 13G/A - Senti Biosciences, Inc. (0001854270) (Subject)
SC 13G - Senti Biosciences, Inc. (0001854270) (Subject)
SC 13G/A - Senti Biosciences, Inc. (0001854270) (Subject)
SC 13G/A - Senti Biosciences, Inc. (0001854270) (Subject)
SC 13G - Senti Biosciences, Inc. (0001854270) (Subject)
– Approximately $10 million additional investment in private placement equity financing – – $1.5 million from CIRM grant first announced in June 2024 – – Cash runway guidance extended into 2026 – SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it has secured an additional investment of approximately $10.0 million in gross proceeds from Celadon Partners adding to the previously announced PIPE financing round. This additional funding brings the total
– Dose-finding clinical trial in China designed to evaluate safety and preliminary anti-tumor activity of SN301A (SENTI-301A manufactured in China) in hepatocellular carcinoma ("HCC") – SOUTH SAN FRANCISCO, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that the first patient has been dosed in the pilot trial of SN301A in HCC in mainland China in collaboration with Celest Therapeutics (Shanghai) Co. Ltd ("Celest"). SN301A utilizes the anti-GPC3 + crIL-15 (each as defined below) SENTI-301A Gene
SOUTH SAN FRANCISCO, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that on November 26, 2024, the Compensation Committee of Senti Bio's Board of Directors granted to three new employees stock options to purchase an aggregate of 49,778 shares of the Company's common stock with a per share exercise price of $2.11. These awards were made under the Company's 2022 Inducement Equity Plan (the "Plan"). The above-described awards were each granted as an inducement material to the employees entering
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, has entered into a securities purchase agreement with certain existing and new accredited investors to issue and sell an aggregate of 16,713 shares of Series A Convertible Preferred Stock (the "Preferred Stock") through a private investment in public equity (the "PIPE") financing. Senti Bio anticipates the gross proceeds from the PIPE financing to be approximately $37.6 million, before deducting offering expenses. In addition,
– 2 of 3 patients achieved MRD negative CR in the first dose level evaluated in the trial with a generally well-tolerated preliminary safety profile – – Dose escalation is continuing with additional response and durability data expected in 2025 – – Conference call scheduled on December 3 at 7:30am ET – SOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported positive initial clinical data from a Phase 1 clinical trial of SENTI-202, a potential first-i
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it has appointed Fran Schulz, a highly experienced biotechnology and financial executive, to the Senti Bio Board of Directors ("Board"). "We are excited to welcome Fran to the Senti Bio Board of Directors," said Timothy Lu, MD, PhD, Chief Executive Officer and Co-Founder of Senti Bio. "Fran's deep expertise in the life sciences industry—spanning finance, strategic planning, operations, and transactions—wi
SOUTH SAN FRANCISCO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for the third quarter of 2024 and provided a summary of recent pipeline and corporate highlights. "Over the past quarter, we have continued to execute on our clinical milestones and look forward to sharing initial results from the clinical trial of SENTI-202 before 2024 year-end," said Timothy Lu, MD, PhD, Chief Executive Officer and Co-Founder of Senti Bio. "As we look toward 2025, we anticipate sharing add
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, including SENTI-202, a Logic Gated off-the-shelf CAR-NK investigational cell therapy in Phase 1 clinical trials, today announced its participation at the following investor conferences: H.C. Wainwright's 26th Annual Global Investment ConferenceFormat: Presentation and 1x1 MeetingsLocation: New York, NYPlease click here to access the pre-recorded presentation (available September 9, 2024, at 7:00 a.m. ET)Chardan's 8th Annual Genetic Medic
– Dose finding ongoing in Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including AML – – Commencement of $8 million grant award from CIRM for the clinical development of SENTI-202 – SOUTH SAN FRANCISCO, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for the second quarter of 2024 and provided a summary of recent corporate and pipeline highlights. "We have demonstrated important progress year to date, dosi
SOUTH SAN FRANCISCO, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced the commencement of a grant award of $8 million from the California Institute for Regenerative Medicines ("CIRM"). Pursuant to the executed agreement with CIRM, the first tranche of the grant award is expected to be received in August 2024. The CIRM grant will support the ongoing clinical development of SENTI-202, a potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer ("CAR-NK") investigational cell the
4 - Senti Biosciences, Inc. (0001854270) (Issuer)
4 - Senti Biosciences, Inc. (0001854270) (Issuer)
3 - Senti Biosciences, Inc. (0001854270) (Issuer)
4 - Senti Biosciences, Inc. (0001854270) (Issuer)
3 - Senti Biosciences, Inc. (0001854270) (Issuer)
4 - Senti Biosciences, Inc. (0001854270) (Issuer)
4 - Senti Biosciences, Inc. (0001854270) (Issuer)
4 - Senti Biosciences, Inc. (0001854270) (Issuer)
4 - Senti Biosciences, Inc. (0001854270) (Issuer)
4 - Senti Biosciences, Inc. (0001854270) (Issuer)
PRE 14A - Senti Biosciences, Inc. (0001854270) (Filer)
8-K - Senti Biosciences, Inc. (0001854270) (Filer)
D - Senti Biosciences, Inc. (0001854270) (Filer)
8-K - Senti Biosciences, Inc. (0001854270) (Filer)
8-K - Senti Biosciences, Inc. (0001854270) (Filer)
144 - Senti Biosciences, Inc. (0001854270) (Subject)
8-K - Senti Biosciences, Inc. (0001854270) (Filer)
8-K - Senti Biosciences, Inc. (0001854270) (Filer)
10-Q - Senti Biosciences, Inc. (0001854270) (Filer)
8-K - Senti Biosciences, Inc. (0001854270) (Filer)
Morgan Stanley initiated coverage of Senti Bio with a rating of Equal-Weight and set a new price target of $7.50
– Dose-finding clinical trial in China designed to evaluate safety and preliminary anti-tumor activity of SN301A (SENTI-301A manufactured in China) in hepatocellular carcinoma ("HCC") – SOUTH SAN FRANCISCO, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that the first patient has been dosed in the pilot trial of SN301A in HCC in mainland China in collaboration with Celest Therapeutics (Shanghai) Co. Ltd ("Celest"). SN301A utilizes the anti-GPC3 + crIL-15 (each as defined below) SENTI-301A Gene
SOUTH SAN FRANCISCO, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that on November 26, 2024, the Compensation Committee of Senti Bio's Board of Directors granted to three new employees stock options to purchase an aggregate of 49,778 shares of the Company's common stock with a per share exercise price of $2.11. These awards were made under the Company's 2022 Inducement Equity Plan (the "Plan"). The above-described awards were each granted as an inducement material to the employees entering
– 2 of 3 patients achieved MRD negative CR in the first dose level evaluated in the trial with a generally well-tolerated preliminary safety profile – – Dose escalation is continuing with additional response and durability data expected in 2025 – – Conference call scheduled on December 3 at 7:30am ET – SOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported positive initial clinical data from a Phase 1 clinical trial of SENTI-202, a potential first-i
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it has appointed Fran Schulz, a highly experienced biotechnology and financial executive, to the Senti Bio Board of Directors ("Board"). "We are excited to welcome Fran to the Senti Bio Board of Directors," said Timothy Lu, MD, PhD, Chief Executive Officer and Co-Founder of Senti Bio. "Fran's deep expertise in the life sciences industry—spanning finance, strategic planning, operations, and transactions—wi
SOUTH SAN FRANCISCO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for the third quarter of 2024 and provided a summary of recent pipeline and corporate highlights. "Over the past quarter, we have continued to execute on our clinical milestones and look forward to sharing initial results from the clinical trial of SENTI-202 before 2024 year-end," said Timothy Lu, MD, PhD, Chief Executive Officer and Co-Founder of Senti Bio. "As we look toward 2025, we anticipate sharing add
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, including SENTI-202, a Logic Gated off-the-shelf CAR-NK investigational cell therapy in Phase 1 clinical trials, today announced its participation at the following investor conferences: H.C. Wainwright's 26th Annual Global Investment ConferenceFormat: Presentation and 1x1 MeetingsLocation: New York, NYPlease click here to access the pre-recorded presentation (available September 9, 2024, at 7:00 a.m. ET)Chardan's 8th Annual Genetic Medic
– Dose finding ongoing in Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including AML – – Commencement of $8 million grant award from CIRM for the clinical development of SENTI-202 – SOUTH SAN FRANCISCO, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for the second quarter of 2024 and provided a summary of recent corporate and pipeline highlights. "We have demonstrated important progress year to date, dosi
SOUTH SAN FRANCISCO, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced the commencement of a grant award of $8 million from the California Institute for Regenerative Medicines ("CIRM"). Pursuant to the executed agreement with CIRM, the first tranche of the grant award is expected to be received in August 2024. The CIRM grant will support the ongoing clinical development of SENTI-202, a potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer ("CAR-NK") investigational cell the
SOUTH SAN FRANCISCO, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio") , a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that its Board of Directors has determined to effect a one-for-ten (1-for-10) reverse stock split of Senti Bio's common stock, par value $0.0001 per share (the "Common Stock"). The reverse stock split will take effect at 11:59 p.m. EDT on July 17, 2024, and Senti Bio's common stock will begin trading on a split-adjusted basis on The Nasdaq Capital Market as of the opening of trading on July 18, 2024. The CUSIP number of 81726A209 will be
SOUTH SAN FRANCISCO, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that the California Institute for Regenerative Medicines ("CIRM") has awarded an $8 million grant to Senti Bio. The CIRM grant will support the ongoing clinical development of SENTI-202, a potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer ("CAR-NK") investigational cell therapy, for the treatment of relapsed/refractory hematologic malignancies including acute myeloid leukemia ("AML"). The Phase 1 clin